Document And Entity Information
Document And Entity Information | Jul. 11, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Document Period End Date | Jul. 11, 2022 |
Entity Registrant Name | PROKIDNEY CORP. |
Entity Central Index Key | 0001850270 |
Entity Emerging Growth Company | true |
Entity File Number | 001-40560 |
Entity Incorporation, State or Country Code | E9 |
Entity Tax Identification Number | 98-1586514 |
Entity Address, Address Line One | 2000 Frontis Plaza Blvd. |
Entity Address, Address Line Two | Suite 250 |
Entity Address, City or Town | Winston-Salem |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 27103 |
City Area Code | 336 |
Local Phone Number | 999-7029 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Ex Transition Period | false |
Title of 12(b) Security | Class A ordinary shares, $0.0001 par value per share |
Trading Symbol | PROK |
Security Exchange Name | NASDAQ |
Amendment Description | As previously reported in the Current Report on Form 8-K filed by the registrant on July 15, 2022 (the “Original Report”), on July 11, 2022 (the “Closing Date”), ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III (“SCS”)), a Cayman Islands exempted company, consummated the previously announced Business Combination (as defined below) with ProKidney LP, a limited partnership registered under the laws of Ireland (“ProKidney”). In connection with the closing of the Business Combination, the registrant changed its name from “Social Capital Suvretta Holdings Corp. III” to “ProKidney Corp.” ProKidney Corp. will continue the existing business operations of ProKidney as a publicly traded company.As used in this Amendment No. 1 to the Current Report on Form 8-K (“Amendment No. 1”), unless otherwise stated or the context clearly indicates otherwise, the terms the “registrant,” the “Company,” “we,” “us,” and “our” refer to ProKidney Corp., and its subsidiaries at and after the Closing Date and giving effect to the consummation of the Business Combination. This Amendment No. 1 to the Original Report is being filed solely for the purpose of amending the disclosure under Item 2.01 - Completion of Acquisition or Disposition of Assets – Form 10 Information - Management’s Discussion and Analysis of Financial Condition and Results of Operations and the historical financial statements provided under Items 9.01(a) and 9.01(b) in the Original Report to include (i) Management’s Discussion and Analysis of Financial Condition and Results of Operations of ProKidney for the three and six months ended June 30, 2022, (ii) the unaudited condensed consolidated financial statements of ProKidney as of and for the three and six months ended June 30, 2022, and (iii) the unaudited pro forma condensed combined financial information of SCS and ProKidney as of and for the three and six months ended June 30, 2022. |